Loading...
•
Mar 31, 2020
Supernus Q1 2020 Earnings Report
Reported an 11% increase in first quarter revenue and progress in pipeline development.
Key Takeaways
Supernus Pharmaceuticals reported a strong first quarter in 2020 with total revenue reaching $95.0 million, an 11% increase compared to 2019. The company is on track for the launch of SPN-812 and is expanding its portfolio through strategic acquisitions and partnerships.
Total revenue for the first quarter reached $95.0 million, an 11% increase year-over-year.
Net product sales for the first quarter were $92.5 million, also an 11% increase compared to the previous year.
Operating earnings for the first quarter totaled $29.0 million, a 14% increase over 2019.
The company anticipates launching SPN-812 by the end of 2020, pending FDA approval.
Revenue by Segment
Forward Guidance
Given the uncertainty caused by the COVID-19 pandemic, the anticipated second quarter acquisition of the CNS portfolio from US WorldMeds and the impact of the partnership with Navitor Pharmaceuticals, the Company is suspending its previously issued full year 2020 financial guidance. The Company expects to update and reinstate full year 2020 guidance no later than the announcement of second quarter 2020 financial results in August.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...